The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.
Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.
The user started taking oral finasteride after four years on oral minoxidil due to thinning hair in the crown area. They experienced some initial side effects and shedding but are hopeful for regrowth, while continuing with minoxidil.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
The user is 4 months into using a treatment with 5mg Dutasteride and 1.25mg Minoxidil daily, along with vitamin K2 and weekly dermastamping. They report some hairline improvement but no noticeable change in the crown area yet.
The user underwent a biopsy two years ago and was diagnosed with keratosis pilaris, leading to hair issues. They tried treatments including Minoxidil, betamethasone, lymecycline, topical Accutane, and dutasteride, as well as diet changes, without improvement in hair thickness or skin dryness.
The conversation discusses a person's 4-month hair loss treatment regimen using topical minoxidil, finasteride, ketoconazole, a dermastamp, and rosemary and peppermint oils. Progress pictures are shared to show the results.
RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.
The user experienced significant hair regrowth using 5 mg daily oral minoxidil and ketoconazole shampoo, improving from Norwood 3 to Norwood 2. They recommend starting treatment early, noting reduced shedding and stable results.
A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.
A user shared their four-year experience using 0.5mg dutasteride and topical minoxidil once daily for aggressive early hair loss, maintaining their hairline and regrowing hair on the vertex. They've experienced positive social feedback and increased confidence but also deal with dry eyes from dutasteride and worry about its long-term effects and cost.
Creatine generally does not affect hair loss, but some report increased shedding due to higher DHT levels. Many manage hair loss with dutasteride, finasteride, and minoxidil.
The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.
A 31-year-old user shared progress pictures after 4 months on a hair loss routine. The routine includes microneedling twice a month, Hims Min/fin topical, and a collagen peptide supplement.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.
The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.
A 25-year-old has been using finasteride for four years to treat hair loss, starting at age 21, and has experienced significant hair thickening without side effects. Others in the conversation share varied results and experiences with finasteride, with some considering adding minoxidil to their treatment.
The user shared their hair regrowth progress using Finasteride and Minoxidil, showing significant improvement. They are considering adding dutasteride for further recovery and reported no side effects.
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
The user is using a combination of oral finasteride, oral and topical minoxidil, multivitamins, and a derma stamp for hair regrowth. They also use Garnier Fructis Grow Strong Thickening Shampoo and exercise regularly to support hair health.